Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Exploration in Patients With Atrial Fibrillation

Trial Profile

Dose Exploration in Patients With Atrial Fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Aspirin; Warfarin
  • Indications Cardiovascular disorders; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PETRO; PETRO-Ex
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Jan 2009 Extension study status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
    • 15 Jan 2009 Extension study status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top